Chemotherapy-Induced Peripheral Neuropathy: What Nurses and Patients Need to Know | Megha Shah, DNP, FNP, OCN
Peripheral neuropathy is one of the most common and most undertreated side effects of cancer treatment. It affects quality of life in ways that are difficult to quantify and often difficult for patients to describe. In the infusion center, I see the functional impact of neuropathy regularly, patients who can no longer button their shirts, who have stopped walking because their feet feel like they are wearing concrete blocks, or who have modified their diets because they cannot tolerate cold exposure from the refrigerator.
Chemotherapy-induced peripheral neuropathy (CIPN) occurs when chemotherapy damages the peripheral nervous system, affecting sensory, motor, or autonomic nerve fibers. Understanding which drugs cause it, how it presents, and what the current evidence supports for management is fundamental to oncology nursing practice.
Which Drugs Cause CIPN and How
Not all chemotherapy drugs cause peripheral neuropathy, but several of the most commonly used regimens carry significant neuropathy risk. The mechanism differs by drug class, and understanding the mechanism helps nurses anticipate the clinical picture.
Taxanes (paclitaxel, docetaxel, nab-paclitaxel). Taxanes are among the most neurotoxic chemotherapy agents in common use. They work by stabilizing microtubules and disrupting normal cellular division, and that same mechanism interferes with axonal transport in peripheral nerves. Taxane-induced neuropathy is predominantly sensory and typically presents as a stocking-glove distribution of numbness, tingling, and burning in the hands and feet. Paclitaxel carries higher neuropathy risk than docetaxel; nab-paclitaxel has a similar profile to standard paclitaxel in most patients.
Taxane neuropathy can develop acutely, within days of infusion, or cumulatively over a treatment course. The acute form often presents as pain in the muscles and joints (sometimes called paclitaxel-associated acute pain syndrome, or P-APS) that peaks 48 to 72 hours post-infusion and resolves within a week. The cumulative form is the one that tends to persist after treatment ends.
Platinum agents (oxaliplatin, cisplatin, carboplatin). Oxaliplatin is the most neuropathogenic of the platinum agents and the one that deserves the most clinical attention. Like taxanes, it causes both an acute and a chronic form of neuropathy. The acute form is distinctive: exposure to cold temperatures triggers or intensifies symptoms, often presenting as a pharyngo-laryngeal dysesthesia (a sensation of difficulty swallowing or breathing in cold air) that can be alarming to patients. The chronic cumulative form presents as sensory neuropathy similar to taxane-induced CIPN.
Patient teaching about cold avoidance during oxaliplatin therapy is a practical and important nursing intervention. Patients should be advised to avoid cold drinks and cold foods during the acute period following infusion, wear gloves when handling refrigerated items, and avoid cold air exposure on the face and throat. This is not a trivial inconvenience, failure to counsel patients about it consistently leads to distress, unnecessary emergency department visits, and reduced adherence.
Cisplatin causes dose-dependent sensory neuropathy that can be severe and permanent at cumulative doses. Carboplatin carries lower neuropathy risk than cisplatin but should not be assumed to be neuropathy-free, particularly in combination regimens.
Vinca alkaloids (vincristine, vinorelbine, vinblastine). Vincristine is the most neurotoxic of this class. It causes peripheral neuropathy through a different mechanism, disruption of microtubule polymerization rather than stabilization, but the clinical effect on peripheral nerves is similar. Vincristine-induced neuropathy often begins with sensory changes in the fingertips and toes and can progress to motor involvement, including foot drop, which is a serious functional consequence requiring prompt assessment and intervention.
Constipation is a common and often underappreciated autonomic manifestation of vincristine neurotoxicity. Nurses should include assessment of bowel function in every patient receiving vincristine.
Bortezomib (Velcade). This proteasome inhibitor, used in multiple myeloma and some lymphoma regimens, carries significant neuropathy risk. It tends to produce a painful sensory neuropathy that can be severe enough to require dose modification or discontinuation. The subcutaneous route of administration has been associated with lower neuropathy incidence compared to intravenous administration, and many practices have adopted subcutaneous delivery as the default.
Thalidomide and lenalidomide. These immunomodulatory agents carry neuropathy risk, particularly thalidomide, which has a well-characterized and sometimes irreversible neuropathy profile. Lenalidomide’s neuropathy risk is lower but not absent.
Assessment: Making It Systematic
One of the consistent gaps in CIPN management is underassessment. Patients frequently do not volunteer neuropathy symptoms unless directly asked, either because they assume it is expected and unavoidable, or because they are more focused on communicating other concerns during clinic visits.
A structured approach to CIPN assessment should include patient-reported outcomes. The FACT/GOG-Ntx subscale and the European Organisation for Research and Treatment of Cancer (EORTC) CIPN-20 are validated patient-reported tools. At minimum, nurses should ask specifically about the presence, location, and functional impact of numbness, tingling, burning, and pain, and about whether symptoms are interfering with activities of daily living such as walking, using hands, fastening clothing, and sleeping.
Motor assessment should include observation of gait and balance, grip strength, and fine motor coordination as appropriate for the patient’s treatment history and symptom burden. Patients with significant motor involvement need referral to physical and occupational therapy.
A key nursing responsibility is timely documentation and communication of neuropathy symptoms using a standardized grading system. The Common Terminology Criteria for Adverse Events (CTCAE) grades neuropathy from 1 (mild, no functional limitation) to 4 (severe functional limitation, life-threatening). Grade 3 or 4 neuropathy typically triggers dose modification or treatment hold, and the oncology team cannot make that clinical decision without accurate nursing documentation.
Management: What the Evidence Supports
There is no approved pharmacologic agent for the prevention of CIPN, despite significant research interest in this area. Duloxetine (Cymbalta) is the only agent with a meaningful evidence base for treatment of established, painful CIPN, supported by an ASCO clinical practice guideline recommendation. It does not reverse the neuropathy, but it can reduce symptom burden in patients with painful CIPN.
As an NP, I can prescribe duloxetine for patients with painful CIPN in collaboration with the treating oncologist, and this is a conversation worth initiating proactively rather than waiting for patients to report intolerable symptoms.
Other agents that are sometimes used, gabapentin, pregabalin, tricyclic antidepressants, have weaker evidence specifically for CIPN and are generally considered second-line options when duloxetine is not tolerated or effective.
Non-pharmacologic interventions with emerging evidence include exercise, balance training, and scrambler therapy. Exercise, particularly walking and low-impact aerobic activity, has the best evidence base as a non-pharmacologic intervention for CIPN and should be recommended to patients who are physically able. Balance training is particularly important for patients with sensory neuropathy in the feet, given the fall risk associated with proprioceptive loss.
Referral to physical therapy for balance and gait assessment is appropriate for patients with moderate to severe lower extremity neuropathy and should be initiated proactively rather than after a fall.
Patient Teaching Points
For patients experiencing CIPN, nursing education should cover the following:
Report new or worsening numbness, tingling, burning, or pain at each visit, do not assume the care team already knows how you are feeling.
Take fall precautions seriously: non-slip footwear, bathroom safety equipment, and stair handrails matter when proprioception is impaired.
For patients on oxaliplatin: avoid cold exposures during the days following infusion as instructed by your care team.
For patients on vincristine: report changes in bowel habits, weakness, or difficulty walking promptly.
Report any new difficulty with fine motor tasks, handling medications, using utensils, managing personal care, because these may indicate motor involvement that warrants closer assessment.
CIPN is not inevitable for every patient on a neurotoxic regimen, but its likelihood is high enough that proactive, consistent assessment and education should be standard of care. The patients who do best are those whose symptoms are caught early, documented accurately, and communicated to the team in time to act.